Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Skin sodium accumulation in chronic kidney disease
NL-OMON53426Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of hydrochlorothiazide, spironolactone and lercanidipine in chronic kidney disease (CKD) (4 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Incidence of cardiovascular events and renal replacement therapy, Skin sodium content difference between different treatments and 3 more. Started Jan 2025; status: recruiting.
02
Drugs
hydrochlorothiazidespironolactonelercanidipine
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON53426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53426.